Announcements Trials
Browse Landscape

Phase

Phase 2 77Phase 1 40Phase 1/2 14Phase 3 10Phase 4 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × Dasatinib × Clear all
NCT01482728 2016-05-13

Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

University of Virginia

Phase EARLY_PHASE1 Completed
12 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡